Floatz logo

Semaglutide

Inherited Obesity

Prof. Dr. Martin Wabitschprotein_peptideUnknownActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Inherited Obesity cohort.

Asset / SponsorPhaseRating
Setmelanotide
Rhythm Pharmaceuticals, Inc.
Phase 3BBB
Mibavademab
Regeneron Pharmaceuticals
Phase 3B
HUMAN FAECAL MATTER
Federal Research and Clinical Center of Physical-Chemical Medicine
N/AD

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseActive
A
Indicative · Phase 4
81 / 100
View asset →
polycystic ovary syndromeActive
BBB
Indicative · Phase 4
79 / 100
View asset →
type 2 diabetes mellitusActive
BBB
Indicative · Phase 4
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →